Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation

Hermann Einsele, Per Ljungman, Michael Boeckh

Blood (2020) 135 (19): 1619–1629.

https://doi.org/10.1182/blood.2019000956

Published: 2020

Journal Articles

Epidemiology of Post-Transplant Lymphoproliferative Disorders in Children with Solid Organ Transplant over 34 Years of a Single Center Experience

Marta Rojas Vasquez, MD FRCPC, Anthea Peters, MSc, MD FRCPC, Raymond Lai, MD PhD FRCP, Curtis Mabilangan, MSc, Burton Catherine, MD FRCPC, Jutta Preiksaitis, MDFRCPC

Blood (2019) 134 (Supplement_1): 1602.

https://doi.org/10.1182/blood-2019-125344

Published: 2019

Journal Articles

High Rates of Varicella Zoster Virus Antibody Seroconversion after Administration of the Adjuvanted, Recombinant Varicella Zoster Vaccine in Multiple Myeloma Patients Undergoing Active Treatment

Karen Sweiss, PharmD, Gregory Sampang Calip, PharmD,MPH,PhD, John P Galvin, MDMS,MPH, Damiano Rondelli, MD, Pritesh Patel, MB, ChB

Blood (2019) 134 (Supplement_1): 3081.

https://doi.org/10.1182/blood-2019-131914

Published: 2019

Journal Articles

Anti-Viral Prophylaxis for Hepatitis B Virus Is Associated with Improved Outcome in Patients with Diffuse Large B Cell Lymphoma in Taiwan - a Population-Based Study between 2011 and 2015

Huai-Hsuan Huang, Fei-Yuan Hsiao, PhD Associate Professor, Ho-Min Chen, M.S., Chen-Yu Wang, PhD, Hwei-Fang Tien, MD, PhD, Bor-Sheng Ko, MD PhD

Blood (2019) 134 (Supplement_1): 4765.

https://doi.org/10.1182/blood-2019-127972

Published: 2019

Journal Articles

High Incidence of Herpes Zoster after Cord Blood Hematopoietic Cell Transplant Despite Longer Duration of Antiviral Prophylaxis

Elisabetta Xue, MD, Hu Xie, Wendy Leisenring, ScD, Louise E Kimball, PhD RN, Sonia Goyal, Lisa Chung, Rachel Blazevic, Byron Maltez, Ann Dahlberg, MD, Rachel B. Salit, MD, Colleen Delaney, MD MSc, Steven A. Pergam, MDMPH, Michael Boeckh, MD, Filippo Milano, MD PhD, Joshua Aiden Hill, MD

Blood (2019) 134 (Supplement_1): 4556.

https://doi.org/10.1182/blood-2019-124211

Published: 2019

Journal Articles

A National, Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma: Updated Results from the Miroir Study

Blood (2018) 132 (Supplement 1): 3238.

https://doi.org/10.1182/blood-2018-99-111892

Published: 2018

Journal Articles

Impact of Prophylactic Antiviral Therapy on Clinical Outcomes of Hepatitis B Virus Surface Antigen Positive Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab-Containing Chemotherapy

Blood (2018) 132 (Supplement 1): 4209.

https://doi.org/10.1182/blood-2018-99-114850

Published: 2018

Journal Articles

Reactivation of Hepatitis B Virus Infection in Aplastic Anemia Patients Receiving Immunosuppressive Therapy

Hua Yin, Suli Wang, Xingyu Lu, Wenyi Shen, MD, Ruinan Lu, Yu Zhu, MD PhD, Kourong Miao, Ming Hong, MD PhD, Shuai Wang, MD PhD, Jianfu Zhang, Chun Qiao, Yujie Wu, Xuemei Wu, Guangsheng He, Jianyong Li, MD PhD

Blood (2018) 132 (Supplement 1): 5107.

https://doi.org/10.1182/blood-2018-99-118836

Published: 2018

Journal Articles

Risk of Infectious Complications in Patients with Chronic Lymphocytic Leukemia in the Era of BCR Inhibitors: A Retrospective Single Institution Experience

Francesco Autore, MD, Idanna Innocenti, MD PhD, Francesca Morelli, Federica Sora, Andrea Corbingi, MD, Denise Soldati, Luana Fianchi, MD, Marianna Criscuolo, Livio Pagano, Andrea Bacigalupo, MD, Simona Sica, MD, Luca Laurenti, MD

Blood (2018) 132 (Supplement 1): 5552.

https://doi.org/10.1182/blood-2018-99-119654

Published: 2018

Journal Articles

Hepatitis B Virus (HBV) Screening and Associated Outcomes in Malignant Hematology Patients Receiving Rituximab Therapy within the Rossy Cancer Network

Shen Li, MD, Allaa Ali, MPH, Alexander Lawandi, MD BS, BA, MSc, Myriam Fernandez, RN, Caroline Rousseau, PhD, Doneal Thomas, M.Phil, M.Sc, Sarit Assouline, Chantal Cassis, MD, Todd Campbell Lee, MD MPH, Kelly L. Davison, MD PhD

Blood (2018) 132 (Supplement 1): 2256.

https://doi.org/10.1182/blood-2018-99-119079

Published: 2018

Journal Articles

Racial Disparities in the Utilization of Recommended Supportive Care Among Patients with Multiple Myeloma in the United States

Smith Giri, MBBS, Weiwei Zhu, MPH, Rong Wang, PhD, Amer M. Zeidan, MBBS, MHS, Nikolai A. Podoltsev, MD PhD, Steven D. Gore, MD, Xiaomei Ma, PhD, Amy J. Davidoff, PhD MS, Scott F Huntington, MDMPH

Blood (2018) 132 (Supplement 1): 978.

https://doi.org/10.1182/blood-2018-99-119791

Published: 2018

Journal Articles

High Incidence of Hepatitis B Viral Reactivation in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Jieun Uhm, MD PhD, Sung-Hyun Kim, MD PhD, Sukjoong Oh, MD PhD, Dae Young Zang, MD PhD, Young Rok Do, PhD MD, Won Sik Lee, MD PhD, Myung Hee Chang, MD, Sung-Eun Lee, MD PhD, Dong-Wook Kim, MD PhD

Blood (2018) 132 (Supplement 1): 3010.

https://doi.org/10.1182/blood-2018-99-117543

Published: 2018

Journal Articles

Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center

Kerry A. Rogers, MD, Mousa Luay, MD, Qiuhong Zhao, MS, Tracy Wiczer, PharmD, Lauren Levine, PharmD, El Boghdadly Zeinab, MBBCh, James S. Blachly, MD, John C. Byrd, MD, Tomas Guerrero, MD, Jeffrey A. Jones, MD MPH, MBA, Shindiapina Polina, MD PhD, Audrey Sigmund, MD, Matthew Sullivan, MD, Farrukh T. Awan, MD MS, Jennifer A. Woyach, MD

Blood (2017) 130 (Supplement 1): 830.

https://doi.org/10.1182/blood.V130.Suppl_1.830.830

Published: 2017

Journal Articles

Managing the Risk of Hepatitis B Virus Reactivation in Patients with B-Cell Lymphomas Treated with Obinutuzumab or Rituximab Immunochemotherapy

Shigeru Kusumoto, MD, Luca Arcaini, MD, Xiaonan Hong, Jie Jin, Won Seog Kim, MD, Ph. D., Yok Lam Kwong, Marion Peters, Yasuhito Tanaka, Andrew D. Zelenetz, MD PhD, Hiroshi Kuriki, Günter Fingerle-Rowson, Tina Nielsen, Eisuke Ueda, Hanna Piper-Lepoutre, Gila Sellam, Kensei Tobinai, MD PhD

Blood (2017) 130 (Supplement 1): 2823.

https://doi.org/10.1182/blood.V130.Suppl_1.2823.2823

Published: 2017

Journal Articles

Hepatitis B Virus Seropositivity in Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitors: Preliminary Results of a Single-Center Cross-Sectional Study

Nurgul Ozgur Yurttas, MD, Burak Sarilar, MD, Ahmet Emre Eskazan, MD, Deniz Ozmen, MD, Dilek Keskin, MD, Sevil Sadri, MD, Selin Berk, MD, Ayse Salihoglu, MD, M. Cem Ar, MD PhD, Seniz Ongoren, MD, Zafer Baslar, MD, Yildiz Aydin, MD, Teoman Soysal, MD

Blood (2017) 130 (Supplement 1): 2888.

https://doi.org/10.1182/blood.V130.Suppl_1.2888.2888

Published: 2017

Journal Articles

The Incidence of HBV Reactivation in Patients Receiving First-Line R-CHOP Chemotherapy: Three-Year Follow-up Results from a Prospective, Observational Study

Blood (2017) 130 (Supplement 1): 5213.

https://doi.org/10.1182/blood.V130.Suppl_1.5213.5213

Published: 2017

Journal Articles

Differences in Infection Prophylaxis between Pediatric AML Study Groups within the International BFM Study Group

Kim Klein, MD MSc, Henrik Hasle, MD PhD, Jonas Abrahamsson, MD PhD, Barbara De Moerloose, MD PhD, Gertjan J.L. Kaspers, MD PhD

Blood (2017) 130 (Supplement 1): 2104.

https://doi.org/10.1182/blood.V130.Suppl_1.2104.2104

Published: 2017

Journal Articles

Shingles Occurs in Only 0.5% of Myeloma Patients on Any Dose of Antiviral Prophylaxis

Jacqueline Chu, BA, Syed Basir Hussaini, BS, Nidhi Sharma, PhD, Nita Williams, BS, Don M Benson, Jr., MD PhD, Ashley E Rosko, MD, Yvonne A Efebera, MD, Craig C Hofmeister, MDMPH

Blood (2017) 130 (Supplement 1): 4645.

https://doi.org/10.1182/blood.V130.Suppl_1.4645.4645

Published: 2017

Journal Articles

Use of Herpes Zoster Prophylaxis in Myeloma Patients Treated with Proteasome Inhibitors

Siyang Leng, MD, Suzanne Lentzsch, MD PhD, Yanhan Shen, MS, Jason D Wright, MD MS, Dawn Hershman, MD MS, Alfred I Neugut, MD PhD

Blood (2017) 130 (Supplement 1): 2117.

https://doi.org/10.1182/blood.V130.Suppl_1.2117.2117

Published: 2017

Journal Articles

HHV-6 Prophylaxis with Foscanet Improves Hematopoietic Engraftment after Umbilical Cord Blood Transplantation

Nelli Bejanyan, MD, John Rogosheske, PharmD, Todd E. DeFor, MS, Jaime Green, MD, Troy C Lund, MD PhD, Daniel J. Weisdorf, MD, John E. Wagner, MD, Claudio G Brunstein, MD PhD

Blood (2017) 130 (Supplement 1): 1951.

https://doi.org/10.1182/blood.V130.Suppl_1.1951.1951

Published: 2017

NARROW

How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation

Epidemiology of Post-Transplant Lymphoproliferative Disorders in Children with Solid Organ Transplant over 34 Years of a Single Center Experience

High Rates of Varicella Zoster Virus Antibody Seroconversion after Administration of the Adjuvanted, Recombinant Varicella Zoster Vaccine in Multiple Myeloma Patients Undergoing Active Treatment

Anti-Viral Prophylaxis for Hepatitis B Virus Is Associated with Improved Outcome in Patients with Diffuse Large B Cell Lymphoma in Taiwan - a Population-Based Study between 2011 and 2015

High Incidence of Herpes Zoster after Cord Blood Hematopoietic Cell Transplant Despite Longer Duration of Antiviral Prophylaxis

A National, Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma: Updated Results from the Miroir Study

Impact of Prophylactic Antiviral Therapy on Clinical Outcomes of Hepatitis B Virus Surface Antigen Positive Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab-Containing Chemotherapy

Reactivation of Hepatitis B Virus Infection in Aplastic Anemia Patients Receiving Immunosuppressive Therapy

Risk of Infectious Complications in Patients with Chronic Lymphocytic Leukemia in the Era of BCR Inhibitors: A Retrospective Single Institution Experience

Hepatitis B Virus (HBV) Screening and Associated Outcomes in Malignant Hematology Patients Receiving Rituximab Therapy within the Rossy Cancer Network

Racial Disparities in the Utilization of Recommended Supportive Care Among Patients with Multiple Myeloma in the United States

High Incidence of Hepatitis B Viral Reactivation in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center

Managing the Risk of Hepatitis B Virus Reactivation in Patients with B-Cell Lymphomas Treated with Obinutuzumab or Rituximab Immunochemotherapy

Hepatitis B Virus Seropositivity in Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitors: Preliminary Results of a Single-Center Cross-Sectional Study

The Incidence of HBV Reactivation in Patients Receiving First-Line R-CHOP Chemotherapy: Three-Year Follow-up Results from a Prospective, Observational Study

Differences in Infection Prophylaxis between Pediatric AML Study Groups within the International BFM Study Group

Shingles Occurs in Only 0.5% of Myeloma Patients on Any Dose of Antiviral Prophylaxis

Use of Herpes Zoster Prophylaxis in Myeloma Patients Treated with Proteasome Inhibitors

HHV-6 Prophylaxis with Foscanet Improves Hematopoietic Engraftment after Umbilical Cord Blood Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only